Why Is Cancer-Focused Aadi Bioscience Stock Trading Higher On Friday?
Why Is Cancer-Focused Aadi Bioscience Stock Trading Higher On Friday?
Aadi will pay aggregate upfront payments of $44 million for in-licensing such ADC programs.On Thursday, Aadi Bioscience, Inc. (NASDAQ:AADI) entered into an exclusive license agreement for the development and global commercialization of a three-asset portfolio of preclinical antibody-drug conjugates (ADCs), in collaboration with WuXi Biologics and Hangzhou DAC Biotechnology Co., Ltd.
在週四，Aadi Bioscience, Inc. (納斯達克:AADI) 與WuXi生物製品和杭州DAC生物技術有限公司簽署了一項獨家許可協議，以開發和全球商業化一個包含三個前臨牀抗體藥物結合物（ADCs）組合的項目。
Per the terms of the license agreement, Aadi is granted exclusive rights to certain patents and know-how pertaining to three preclinical ADC programs leveraging Hangzhou DAC's CPT113 linker payload technology.
根據許可協議的條款，Aadi獲得了與三個前臨牀ADC項目相關的某些專利和技術的獨家權利，這些項目利用了杭州DAC的CPT113連接子負載技術。
Also Read: Cancer Player Aadi Bioscience Downgraded: Analyst Highlights 'Worse Than Expected' Response Rates.
另請閱讀：癌症公司Aadi Bioscience被下調評級：分析師強調回應率『低於預期』。
Aadi will pay aggregate upfront payments of $44 million for in-licensing such ADC programs.
Aadi將支付總計4400萬美元的前期付款，以獲得該ADC項目的許可。
Additionally, Aadi will pay cumulative development milestone payments of up to $265 million, cumulative commercial milestone payments of up to $540 million, and single-digit sales royalties.
此外，Aadi將支付高達26500萬美元的累計開發里程碑付款，高達54000萬美元的累計商業里程碑付款，以及單數銷售版稅。
To support this transaction, Aadi entered into a subscription agreement with certain qualified institutional buyers and accredited investors for a private investment in public equity financing of approximately $100 million.
爲了支持這一交易，Aadi與一些合格的機構買家和認證投資者簽訂了認購協議，以進行大約10000萬美元的公開股票融資。
The company is selling 21.59 million shares at $2.40 per share.
該公司以每股2.40美元的價格出售2159萬股。
In August, Aadi Bioscience announced it would halt the registration-intended PRECISION1 trial of nab-sirolimus in patients with solid tumors harboring TSC1 or TSC2 inactivating alterations.
在八月，Aadi Bioscience宣佈將暫停針對攜帶TSC1或TSC2失活改變的實體腫瘤患者的註冊意圖PRECISION1試驗。
An analysis by the Independent Data Monitoring Committee demonstrated that the study was unlikely to exceed an efficacy threshold necessary to support an accelerated approval, the key goal of this Phase 2 study.
獨立數據監測委員會的分析表明，該研究不太可能超過支持加速審批所需的有效性閾值，這是這項二期研究的關鍵目標。
Price Action: AADI stock is up 24.1% at $2.87 during the premarket session at last check Friday.
價格走勢：在最後一次檢查時，AADI股票在盤前交易中上漲了24.1%，達到了2.87美元。
- FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood
- FDA批准Ionis Pharmaceuticals治療罕見遺傳疾病的療法，以降低血液中高水平的脂肪。
譯文內容由第三人軟體翻譯。
